Logo image of PEPG

PEPGEN INC (PEPG) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PEPG - US7133171055 - Common Stock

5.11 USD
-0.33 (-6.07%)
Last: 12/8/2025, 9:52:07 AM
Fundamental Rating

3

Overall PEPG gets a fundamental rating of 3 out of 10. We evaluated PEPG against 531 industry peers in the Biotechnology industry. While PEPG has a great health rating, there are worries on its profitability. PEPG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

PEPG had negative earnings in the past year.
PEPG had a negative operating cash flow in the past year.
In the past 5 years PEPG always reported negative net income.
PEPG had a negative operating cash flow in each of the past 5 years.
PEPG Yearly Net Income VS EBIT VS OCF VS FCFPEPG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

PEPG has a Return On Assets of -49.23%. This is comparable to the rest of the industry: PEPG outperforms 50.66% of its industry peers.
The Return On Equity of PEPG (-57.35%) is better than 61.96% of its industry peers.
Industry RankSector Rank
ROA -49.23%
ROE -57.35%
ROIC N/A
ROA(3y)-48.79%
ROA(5y)-36.64%
ROE(3y)-62.28%
ROE(5y)-45.33%
ROIC(3y)N/A
ROIC(5y)N/A
PEPG Yearly ROA, ROE, ROICPEPG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PEPG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PEPG Yearly Profit, Operating, Gross MarginsPEPG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, PEPG has more shares outstanding
The number of shares outstanding for PEPG has been increased compared to 5 years ago.
There is no outstanding debt for PEPG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PEPG Yearly Shares OutstandingPEPG Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
PEPG Yearly Total Debt VS Total AssetsPEPG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 5.08 indicates that PEPG is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 5.08, PEPG is doing good in the industry, outperforming 73.07% of the companies in the same industry.
PEPG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.08
ROIC/WACCN/A
WACCN/A
PEPG Yearly LT Debt VS Equity VS FCFPEPG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

PEPG has a Current Ratio of 13.15. This indicates that PEPG is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PEPG (13.15) is better than 88.51% of its industry peers.
A Quick Ratio of 13.15 indicates that PEPG has no problem at all paying its short term obligations.
PEPG has a better Quick ratio (13.15) than 88.51% of its industry peers.
Industry RankSector Rank
Current Ratio 13.15
Quick Ratio 13.15
PEPG Yearly Current Assets VS Current LiabilitesPEPG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

1

3. Growth

3.1 Past

PEPG shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.98%.
EPS 1Y (TTM)4.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PEPG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.96% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.26%
EPS Next 2Y23.54%
EPS Next 3Y17.15%
EPS Next 5Y15.96%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PEPG Yearly Revenue VS EstimatesPEPG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
PEPG Yearly EPS VS EstimatesPEPG Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15 -20

0

4. Valuation

4.1 Price/Earnings Ratio

PEPG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PEPG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PEPG Price Earnings VS Forward Price EarningsPEPG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PEPG Per share dataPEPG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEPG's earnings are expected to grow with 17.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.54%
EPS Next 3Y17.15%

0

5. Dividend

5.1 Amount

No dividends for PEPG!.
Industry RankSector Rank
Dividend Yield N/A

PEPGEN INC

NASDAQ:PEPG (12/8/2025, 9:52:07 AM)

5.11

-0.33 (-6.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)02-23 2026-02-23/amc
Inst Owners90.52%
Inst Owner Change137.57%
Ins Owners0.13%
Ins Owner Change3.88%
Market Cap351.31M
Revenue(TTM)N/A
Net Income(TTM)-93.56M
Analysts85
Price Target10.2 (99.61%)
Short Float %3.25%
Short Ratio0.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.42%
Min EPS beat(2)9.77%
Max EPS beat(2)17.07%
EPS beat(4)3
Avg EPS beat(4)4.82%
Min EPS beat(4)-25.27%
Max EPS beat(4)17.71%
EPS beat(8)6
Avg EPS beat(8)8.01%
EPS beat(12)9
Avg EPS beat(12)11.96%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)17.65%
PT rev (3m)42.86%
EPS NQ rev (1m)16.61%
EPS NQ rev (3m)32.22%
EPS NY rev (1m)2.94%
EPS NY rev (3m)18.13%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.15
P/tB 2.15
EV/EBITDA N/A
EPS(TTM)-2.82
EYN/A
EPS(NY)-1.35
Fwd EYN/A
FCF(TTM)-1.25
FCFYN/A
OCF(TTM)-1.24
OCFYN/A
SpS0
BVpS2.37
TBVpS2.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.23%
ROE -57.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.79%
ROA(5y)-36.64%
ROE(3y)-62.28%
ROE(5y)-45.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 34.21%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.15
Quick Ratio 13.15
Altman-Z 5.08
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)339.96%
Cap/Depr(5y)261.35%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.21%
EPS Next Y16.26%
EPS Next 2Y23.54%
EPS Next 3Y17.15%
EPS Next 5Y15.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.24%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-28.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-35.43%
OCF growth 3YN/A
OCF growth 5YN/A

PEPGEN INC / PEPG FAQ

What is the ChartMill fundamental rating of PEPGEN INC (PEPG) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PEPG.


What is the valuation status for PEPG stock?

ChartMill assigns a valuation rating of 0 / 10 to PEPGEN INC (PEPG). This can be considered as Overvalued.


How profitable is PEPGEN INC (PEPG) stock?

PEPGEN INC (PEPG) has a profitability rating of 1 / 10.


What is the expected EPS growth for PEPGEN INC (PEPG) stock?

The Earnings per Share (EPS) of PEPGEN INC (PEPG) is expected to grow by 16.26% in the next year.